The Status of Antibiotics by Raeburn, J. A.
 Res Medica, Spring 1964, Volume 4, Number 2            Page 1 of 5 
Raeburn, J.A.  The Status of Antibiotics, Res Medica 1964, 4(2), pp.19-22      doi: 10.2218/resmedica.v4i2.422 
 
 
 
 
 
The Status of Antibiotics 
 
J. A. Raeburn 
 
Abstract From a dissertation read before the Royal Medical Society on Friday, 1st November, 1963.  Many attribute the earliest recognition of an antibiotic effect to Sir Alexander Fleming. However, in 1877, 50 years before Fleming’s discovery, Pasteur and Joubert described the phenomenon of bacterial antagonism; the process whereby the growth of certain species is inhibited in the presence of others. In the particular case of the anthrax bacillus they found that growth was inhibited in cultures contaminated with ‘common bacteria’ (those types now known as the Enterobacteriaciae). Shortly afterwards the term “antibiosis” was introduced for such antagonism.                       Copyright Royal Medical Society. All rights reserved. The copyright is retained by the author and the Royal Medical Society, except where explicitly otherwise stated. Scans have been produced by the Digital Imaging Unit at Edinburgh University Library. Res Medica is supported by the University of Edinburgh’s Journal Hosting Service: http://journals.ed.ac.uk   ISSN: 2051-7580 (Online)   ISSN: 0482-3206 (Print)     
Res Medica is published by the Royal Medical Society, 5/5 Bristo Square, Edinburgh, EH8 9AL  
Res Medica, Spring 1964, 4(2): 19-22 doi: 10.2218/resmedica.v4i2.422 
The Status of Antibiotics
By J. A .  RAEBURN
From  a dissertation read before the Royal Medical Society on Friday, 1st November, 1963
H is to ry  of anti-microbial th erapy 1
Many attribute the earliest recognition of an 
antibiotic effect to Sir Alexander Fleming. 
However, in 1877, 50 years before Flem ing’s 
discovery, Pasteur and Joubert described the 
phenomenon of bacterial antagonism; the pro­
cess whereby the growth of certain species is 
inhibited in the presence of others. In the 
particular case of the anthrax bacillus they 
found that growth was inhibited in cultures 
contaminated with ‘common bacteria’ (those 
types now known as the E n terobacteriaciae). 
Shortly afterwards the term “antibiosis” was 
introduced for such antagonism.
T h e  problem that faced these early workers 
was to discover substances with selective tox­
icity— substances which destroyed bacteria in 
concentrations having no effect on the cells 
of the body. W ith o u t this selective action, an 
anti-microbial substance is no more than an 
antiseptic. In medicine today it is important 
to remember this distinction. It is difficult to 
justify the use of antibiotic sprays to disinfect 
surgical wards, a use in which it cannot be said 
that selective toxicity is required.
In 1928, Sir Alexander Fleming recognised 
the effect on the growth of staphylococci of 
Penicillium notatum, a fungal contaminant. 
T h e mould had caused the lysis of the sur­
rounding staphylococcal colonies. Ten years 
later Florey and his co-workers published the 
first paper on the clinical use of penicillin.
Since 1939, increased research into the 
development of antibiotics has resulted in over 
a dozen being available for clinical use. W e 
must remember, however, that for each anti­
biotic that has found a place in therapeutics 
today, there are many hundreds that were 
isolated but which were subsequently found to 
be too toxic for clinical use.
Present clinical problems
W hen a clinician decides to treat an infection 
with antibiotics two problems face him; firstly 
drug resistance and secondly drug toxicity.
A. Drug Resistance
It is convenient to consider bacterial resist­
ance to antibiotic action as being either con­
genital or acquired. W e  could regard those 
bacterial species outwith the spectra of 
individual antibiotics as being congenitally 
resistant to such drugs. Treatm ent of infections 
whose causative organisms show such resist­
ance to the antibiotics in use, is doomed to fail.
More pressing at the present time is the 
acquired resistance of bacteria which were 
originally susceptible to given antibiotics. W h at 
is the nature of such resistance? W h a t changes 
occur in bacterial structure to cause it? A  
rational approach to this problem would be to 
determine the precise modes of action of all 
antibiotics and to investigate the changes 
occurring as resistance develops. T h e table 
below summarises the likely modes of action 
of some antibiotics in common use.
ANTIBIOTIC MODE OF ACTION TYPE OF ACTION
PENICILLIN
BACITRACIN
Inhibits cell wall synthesis BACTERICIDAL
STREPTOMYCIN Interferes with 
carbohydrate metabolism
BACTERICIDAL
CHLORAMPHENICOL Interferes with 
protein synthesis
BACTERIOSTATIC
TETRACYCLINES
NOVOBIOCIN
ETC.
BACTERIOSTATIC
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Since precise knowledge of the mechanism 
of antibiotic action is lacking, still less is known 
of the nature of the changes occurring to drug 
resistant types. T w o opposing theories 2• 3 have 
been suggested. These have implications that 
are fundamental to the rational treatment of 
infection.
I. T h e Genetic Theory
This theory states that in bacterial popula­
tions, mutants which arc less susceptible to the 
drug arise spontaneously, and that the produc­
tion of these mutants is independent of ex­
posure to the drug. Subsequently they thrive 
at the expense of the more sensitive strains if 
their environment contains quantities of the 
drug.
II. T h e Adaptive Theory
In this theory it is postulated that the drug 
is a direct stimulus to the development of re­
sistance.
If we are thinking, as we should be, of the 
status of antibiotics in future years, it is the 
second theory that gives more cause for optim ­
ism. For if the use of antibiotics were restricted 
this would lessen the stimulus to the develop­
ment of resistance. Conversely, if resistant 
strains arise despite restricted use of antibiotics, 
there is cause for concern.
T h e evidence for each theory cannot be in­
cluded here, but most workers agree that the 
genetic hypothesises is more able to explain 
certain accepted facts. In accepting this expert 
view, we should realise that the same mechan­
ism need not operate in all eases. T o  support 
such a compromise, we need only think of the 
different patterns of developing resistance. For 
example with the tetracyclines, the first stage 
in the development of resistance forms strains 
that are resistant to only slightly increased con­
centrations of the drug. Subsequently resist­
ance develops to higher and yet higher concen­
trations. By contrast, the resistance which 
develops to streptomycin may ‘ab initio' be of 
uniformly high level.4 T h e pattern of develop­
ing resistance differs; it is likely that so too 
will the mechanisms of developing resistance.
Taking account of both theories, we can 
construct sensible rules for the antibiotic treat­
ment of the individual patient. M oreover 
rational therapy benefits not only the individual 
but also the hospital community, for fewer drug 
resistant strains arise.
Guiding rules for antibiotic therapy
I.
T o  be most effective treatment must be 
started early in the course of the infection 
before many organisms and hence many resist­
ant mutants have developed (genetic theory). 
Here a balance must be struck, for treatment 
must often be delayed until the sensitivity of 
the caustative organism is known. T h e follow­
ing table shows a number of diseases caused by 
micro-organisms that have a consistent suscept­
ibility to antibiotics. In such cases early treat­
ment can be instituted on the strength of a 
clinical diagnosis (see table ii).
A  corollary to this first clinical rule would 
be that in chronic infections of the lungs, the 
urinary tract, etc., little will be gained by hasty 
‘blunderbus’ treatment. In such situations, 
two or three scries of careful bacteriological 
investigations may be required before rational 
antibiotic therapy can begin.
II.
W hen the chosen treatment is started, there 
must be no delay in providing effective tissue 
levels of antibiotic. (Both theories.)
III.
Levels of antibiotic above the minimum in­
hibitory concentration (M IC.) of the infecting 
bacteria must be maintained long enough for 
all the causative organisms to be eradicated 
(adaptive theory).
If the drug concentration at any stage in 
treatment is below the M IC  of the bacteria, 
not only is growth enabled to continue, but 
further, bacteriological evidence indicates that 
some stimulation of growth may occur. (See 
plate.)
IV .
Antibiotic must be eliminated from the body 
as rapidly as possible after successful treatment:
a) In order that the normal bacteriological 
environment is quickly restored.
b) Lest the results of clearance tests are 
falsified.
e.g. After the oral treatment of dysentery, 
antibiotic levels that arc significant may persist 
in the faeces for some time. In such cases, 
certain patients arc declared free from infection 
although they still harbour the causative organ­
ism, temporarily masked by high residual levels 
of antibiotic.
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CLINICAL USUAL CAUSATIVE APPROPRIATE DURATION OF
DIAGNOSIS ORGANISM ANTIBIOTIC TREATMENT
Lobar pneumonia Pneumococcus Benzyl penicillin
Erysipelas 
Scarlet fever
Haemolytic
Streptococci
100.000 units/6 hours 5 days
Enteric fever Salmonella
(typhi and paratpyhi)
Chloramphenicol 
250mg./6 hours 
or Ampicillin"
1 gm./6 hours
14 days 
14-28 days
Typhus fever Rickettsiae Tetracyclines 
250mg./6 hours
7 days
Brucellosis Brucella 14 days
Meningitis a) *Haemophilus Chlorampyenicol 5 days
influenzae 250mg./ 6 hours
b) *Pneumococcus Benzyl penicillin 
20,000 units intrathecally 
+ 250,000 units intramusc
7 days
c) *Meningococcus 
(dose for child of 
1 ½ yrs.)
Sulphadiazine 
500mg./6 hours 
Benzyl penicillin 
250.000 units/6 hours
5-7 days
* Distinguished on the gram-stained film of the CSF. Table ii
This photograph shows part of an agar plate 
on which staphylococci have been evenly distri­
buted. Centrally two 8mm. cups have been 
punched out and in each a known amount of 
streptomycin has been placed. Diffusion of the 
drug through the medium has caused inhibition 
of the growth of the staphylococci inside large 
rings surrounding the cups. The rings of inhi­
bition are sharply demarcated by zones of 
increased grow th. At this point, the antibiotic 
concentration is just below that which causes 
inhibition of growth. If such sub-inhibitory 
concentrations of drug exist in the body, then 
similar increased growth may occur. The main­
tenance of adequate levels at the site of infection 
is of especial importance when using bacterio­
static antibiotics.
Having discussed the phenomenon of drug 
resistance and how it affects the treatment of 
individual cases, let us examine the ‘natural 
history’ of resistance in the community. T h e 
following table shows how the percentage of 
resistant strains of Shigella sonnei has changed 
in the last seven years. T h e figures quoted 
are the approximate values for the Edinburgh 
area.’
Therapeutic agent Percentage resistant
1955 1962
Sulphonamidcs .......... 97% 98%
Streptomycin .......... 2% 27%
Tetracyclines ..........■■ 0% 3%
Chloramphenicol •• 0% 0%
I t  is readily seen that in the case of the first
three substances there has been an increase of 
resistance. There has been no increase in re­
sistance to chloramphenicol, for in this area 
the physicians, well aware of this drug’s tragic 
side effects, do not use it in the treatment of 
dysentery. In the Glasgow area, where more 
chloramphenicol is used, the percentage of 
resistant strains is now about 2% . It is difficult 
to deny the obvious conclusion that with in­
creasing use of antibiotics in a community, the 
proportion of resistant strains increases.
B. Antibiotic Toxicity
T h e vital property of anti-microbial agents 
for parenteral use is selective toxicity. No 
matter how great this is, it is certain that all 
antibiotics at present known will in some situ­
ations have toxic effects, the degree of severity 
of these being dependent on the level in the 
body. Although the many possible therapeutic 
disasters that could be caused by antibiotics 
cannot be elaborated here it must be emphasised 
that no antibiotic can be administered without 
the danger of ill effects. T h e deduction follows 
that a simple rule must be applied before 
ordering a course of antibiotic therapy:—
Antibiotics should only be used in severe 
or potentially severe diseases.
The use of highly toxic antibiotics can only 
be justified if such use is deemed to be life- 
saving, and if adequate facilities exist for the 
estimation of blood levels of the drug. It is 
depressing to think of the fatal marrow aplasias 
that have followed the empirical treatment of 
minor catarrhal conditions with chlorampheni­
col.
It has been suggested that the severe effects 
of the common cold can be forestalled by the 
prophylactic use of antibiotics, and that since
this illness affects millions of people the result 
of such prophylaxis would be of great economic 
significance. However, as a result of the wide­
spread use of antibiotics for this purpose, the 
secondarily invading bacteria would soon be­
come resistant to the antibiotics employed. T h e 
economic benefit would be short-lived. Serious 
thought must be given to the question of treat­
ing such minor complaints.
S U M M A R Y  
I n  this brief review the attempt has been 
made to pose certain questions regarding the 
policy for the use of antibiotics today and in 
future years. There was 110 space to consider 
still more controversial subjects such as the 
prophylactic use of antibiotics6,7 or the value 
of antibiotic combinations.8 T h e rational use 
of these drugs is not simple, and if further in­
discriminate usage continues, the problems of 
the future will become still more alarming. 
Until now, the development of new antibiotics 
has kept pace with the steady increase in resist­
ance to those used currently. It is foolish to 
suppose that the development of new drugs 
will continue. Our legacy, from the previous 
generation has been one of powerful drugs 
which can cure the most severe infections. If 
we misuse this, the legacy of future generations 
will be one of multiple drug resistance in in­
fections more terrible than any we at present 
know.
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